These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 23022003)

  • 1. Re: lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. T. M. van der Sluis, H. N. Bui, E. J. Meuleman, A. C. Heijboer, J. F. Hartman,N. van Adrichem, E. Boevé, W. de Ronde, R. J. van Moorselaar and A. N. Vis. J Urol 2012; 187: 1601–1607.
    Crawford ED; Eisner J; Persson BE
    J Urol; 2013 Mar; 189(3):1168-9. PubMed ID: 23022003
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry: T. M. van der Sluis, H. N. Bui, E. J. Meuleman, A. C. Heijboer, J. F. Hartman, N. van Adrichem, E. Boevé, W. de Ronde, R. J. van Moorselaar and A. N. Vis. J Urol 2012; 187: 1601-1606.
    Oefelein MG
    J Urol; 2012 Nov; 188(5):2020; author reply 2020-1. PubMed ID: 22999544
    [No Abstract]   [Full Text] [Related]  

  • 3. Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry.
    van der Sluis TM; Bui HN; Meuleman EJ; Heijboer AC; Hartman JF; van Adrichem N; Boevé E; de Ronde W; van Moorselaar RJ; Vis AN
    J Urol; 2012 May; 187(5):1601-6. PubMed ID: 22425112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial comment.
    Zlotta AR
    J Urol; 2012 May; 187(5):1606; discussion 1606-7. PubMed ID: 22425082
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
    Guess B; Scholz M
    J Urol; 2001 May; 165(5):1644-5. PubMed ID: 11345950
    [No Abstract]   [Full Text] [Related]  

  • 6. Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients.
    Morote J; Comas I; Ferrer R; Planas J; Celma A; Regis L
    J Biomed Sci; 2017 Oct; 24(1):81. PubMed ID: 29058606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: A Urine Based Genomic Assay to Triage Patients with Hematuria for CystoscopyK. E. M. van Kessel, J. J. de Jong, A. C. J. Ziel-van der Made, H. Roshani, S. M. Haensel, J. H. Wolterbeek, E. R. Boevé, E. H. G. M. Oomens, N. J. van Casteren, M. Krispin, J. L. Boormans, E. W. Steyerberg, W. van Criekinge and E. C. Zwarthoff
    Yin G; Tang J; Wang L
    J Urol; 2020 Nov; 204(5):1062. PubMed ID: 32628098
    [No Abstract]   [Full Text] [Related]  

  • 9. Relationship between body mass index and serum testosterone concentration in patients receiving luteinizing hormone-releasing hormone agonist therapy for prostate cancer.
    van der Sluis TM; van Moorselaar RJ; Meuleman EJ; ter Haar RW; Bui HN; Heijboer AC; Vis AN
    Urology; 2013 May; 81(5):1005-9. PubMed ID: 23465153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Can serum testosterone level measurement extend the intervals of administration of a long-acting LHRH agonist ?].
    Kawamura K
    Hinyokika Kiyo; 2010 Jun; 56(6):301-4. PubMed ID: 20610920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
    Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
    Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. T. Wolters, M. J. Roobol, P. J. van Leeuwen, R. C. van den Bergh, R. F. Hoedemaeker, G. J. van Leenders, F. H. Schröder and T. H. van der Kwast. J Urol 2011;185: 121-125.
    Moore CM; Klotz L; Emberton M
    J Urol; 2011 Sep; 186(3):1158-9; author reply 1159. PubMed ID: 21784490
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy: K. E. M. van Kessel, W. Beukers, I. Lurkin, A. Ziel-van der Made, K. A. van der Keur, J. L. Boormans, L. Dyrskjøt, M. Márquez, T. F. Ørntoft, F. X. Real, U. Segersten, N. Malats, P.-U. Malmström, W. Van Criekinge and E. C. Zwarthoff J Urol 2017;197:590-595.
    Wang Z; Bi SS; Wang L
    J Urol; 2017 Jun; 197(6):1573. PubMed ID: 28259761
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of surgical and medical castration on serum testosterone level in prostate cancer patients.
    Novara G; Galfano A; Secco S; Ficarra V; Artibani W
    Urol Int; 2009; 82(3):249-55. PubMed ID: 19440008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
    Van Poppel H; Klotz L
    Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Place of luteinizing hormone releasing hormone agonists in the treatment of prostatic cancer.
    Dubernard JM; Marechal JM
    J Int Med Res; 1990; 18 Suppl 1():26-30. PubMed ID: 2182354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of pituitary gonadotropin-releasing hormone receptors by pulsatile gonadotropin-releasing hormone injections in male rats. Modulation by testosterone.
    Garcia A; Schiff M; Marshall JC
    J Clin Invest; 1984 Sep; 74(3):920-8. PubMed ID: 6088587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone surge: rationale for gonadotropin-releasing hormone blockers?
    van Poppel H; Nilsson S
    Urology; 2008 Jun; 71(6):1001-6. PubMed ID: 18407326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
    Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
    Urol Int; 2006; 77(2):135-8. PubMed ID: 16888418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.